HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical evaluation of ketoprofen (19.583 R.P.) in rheumatoid arthritis. Double-blind cross-over comparison with indomethacin.

Abstract
In a double-blind cross-over trial the clinical efficacy of ketoprofen (19.583 R.P., Orudis, Profenid N.D.), in comparison with that of indomethacin was investigated in 30 patients with rheumatoid arthritis. The two drugs were each given in a dosage of 150 mg daily for a period of 14 days. The clinical effects of ketoprofen and indomethacin were equal (p less than 0.90), but several side-effects appeared less often and to a milder degree during ketoprofen treatment. The study indicates that ketoprofen may prove to be a valuable drug in the treatment of rheumatoid arthritis.
AuthorsJ Fossgreen, B Kirchheiner, F O Petersen, E Tophoj, E Zachariae
JournalScandinavian journal of rheumatology. Supplement (Scand J Rheumatol Suppl) Vol. 1976 Issue 0 Pg. 93-8 ( 1976) ISSN: 0301-3847 [Print] Norway
PMID790554 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Analgesics
  • Benzophenones
  • Ketoprofen
  • Indomethacin
Topics
  • Adult
  • Aged
  • Analgesics (administration & dosage, adverse effects, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy)
  • Benzophenones (therapeutic use)
  • Clinical Trials as Topic
  • Drug Evaluation
  • Female
  • Gastrointestinal Diseases (chemically induced)
  • Headache (chemically induced)
  • Humans
  • Indomethacin (administration & dosage, adverse effects, therapeutic use)
  • Ketoprofen (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: